Breast cancer survival and in vitro tumor response in the extreme drug resistance assay (Q34647221)

3 August 2017

title

Breast cancer survival and in vitro tumor response in the extreme drug resistance assay (English)

1 reference

3 August 2017

1 reference

Mehta RS

1 reference

3 August 2017

Bornstein R

1 reference

3 August 2017

Yu IR

1 reference

3 August 2017

Parker RJ

1 reference

3 August 2017

McLaren CE

1 reference

3 August 2017

Nguyen KP

1 reference

3 August 2017

Li KT

1 reference

3 August 2017

Fruehauf JP

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

Breast Cancer Research and Treatment

3 August 2017

1 reference

inferred from page(s)

published in

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

225-237

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

7 January 2021

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

7 January 2021

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1010604502627

7 January 2021

Identifiers

DOI

10.1023/A:1010604502627

1 reference

Dimensions Publication ID

3 August 2017

1002331388

0 references

1 reference